Island Pharmaceuticals Limited
Island Pharmaceuticals Limited develops small molecule drugs for antiviral applications, with a principal focus on mosquito- and vector-borne infections such as dengue and Zika, and potential threats such as Marburg. The company emphasizes strategies to accelerate clinical timelines, harnessing compounds with established human safety profiles for rapid advancement through preclinical and clinical stages. It maintains active collaborative research and regulatory engagement, and is publicly listed on the Australian Securities Exchange.
Industries
Nr. of Employees
small (1-50)
Island Pharmaceuticals Limited
Suite 1.01, 117 Camberwell Road, Hawthorn East, VIC, 3123, Australia
Products
An oral antiviral initially developed for other indications and now evaluated for the prevention and treatment of mosquito-borne viral infections such as dengue and Zika. The candidate has a well-established safety profile based on prior clinical trials and has shown efficacy in preclinical animal models.
A clinical-stage small molecule with demonstrated activity against more than 20 RNA viruses. Currently being evaluated for pipeline expansion.
An oral antiviral initially developed for other indications and now evaluated for the prevention and treatment of mosquito-borne viral infections such as dengue and Zika. The candidate has a well-established safety profile based on prior clinical trials and has shown efficacy in preclinical animal models.
A clinical-stage small molecule with demonstrated activity against more than 20 RNA viruses. Currently being evaluated for pipeline expansion.
Expertise Areas
- Antiviral drug development
- Vector-borne infectious diseases
- Drug repurposing
- Clinical trial design and execution
Key Technologies
- Small molecule antivirals
- Oral drug formulations
- Preclinical animal models
- Viral protein nuclear import inhibition
Key People
Managing Director
Non-Executive Chair
Non-Executive Director
Vice President Clinical Product Development
Scientific Advisory Board (Principal Investigator and Virologist)
Scientific Advisory Board (Scientific Consultant – Virology/Antivirals)
Managing Director
Non-Executive Chair
Non-Executive Director
Vice President Clinical Product Development
Scientific Advisory Board (Principal Investigator and Virologist)
Scientific Advisory Board (Scientific Consultant – Virology/Antivirals)
News & Updates
Comprehensive analysis of virologic and immunologic responses in experimentally infected individuals with dengue virus 1.
Evaluation of projected risks of dengue fever under different future climate and development scenarios.
Assessment of the viability of human infection models as a method to test dengue prophylaxis and therapeutics.
Analysis of the potential impact of climate change on future dengue transmission risk in Korea.
Study on nuclear import of viral proteins as a target for dengue antiviral development.
Investigation of nuclear import inhibitors as treatments for Zika infection.
Comprehensive analysis of virologic and immunologic responses in experimentally infected individuals with dengue virus 1.
Evaluation of projected risks of dengue fever under different future climate and development scenarios.
Assessment of the viability of human infection models as a method to test dengue prophylaxis and therapeutics.
Analysis of the potential impact of climate change on future dengue transmission risk in Korea.
Study on nuclear import of viral proteins as a target for dengue antiviral development.
Investigation of nuclear import inhibitors as treatments for Zika infection.